The global hemostats market size is anticipated to USD 5.44 billion by the end of 2025. The growth of this region is accountable for the increasing incidences of sports-related injuries worldwide. A hemostat is a surgical tool used for controlling the flow of blood at the time of performing operations. According to a recent report by Fortune Business Insights titled, “Hemostats Market Size, Share & Industry Analysis, By Product Type (Active Hemostats, Passive Hemostats, Combination Hemostats, Others), By Application (Trauma, Cardiovascular Surgery, General Surgery, Plastic Surgery, Orthopedic Surgery, Neurosurgery, Others), By End, User (Hospitals, Ambulatory Surgical Centers, Tactical Combat Casualty Care Centers, Others) and Regional Forecast, 2018-2025,” the value of this market was USD 3.33 billion in 2017 and is expected to exhibit a CAGR of 6.4% between 2018 and 2025.

For more information in the analysis of this report, visit: https://www.fortunebusinessinsights.com/industry-reports/hemostatic-agents-market-100084

Fortune Business Insights™ lists out the names of market manufacturers. They are as follows:

• Biom’up
• Baxter International Inc.
• Medtronic
• Stryker
• Pfizer Inc.
• CryoLife Inc.
• Ethicon LLC
• Integra Life Sciences
• BD
• Other players

The emergence of COVID-19 has brought the world to a standstill. We understand that this health crisis has brought an unprecedented impact on businesses across industries. However, this, too, shall pass. Rising support from governments and several companies can help in the fight against this highly contagious disease. Some industries are struggling, and some are thriving. Overall, almost every sector is anticipated to be impacted by the pandemic.

Browse Complete Report Details@ https://www.fortunebusinessinsights.com/industry-reports/hemostatic-agents-market-100084

Drivers & Restraints-

Rising Number of Sports Injuries to Augment Growth

The increasing number of accidental cases and the rise in the number of surgical procedures are the major factors promoting hemostat market growth. Additionally, the increasing emphasis on sports and physical activities and the rising number of sports injuries is also expected to aid in the expansion of the market. Besides this, the increasing prevalence of chronic diseases that requires surgical treatment procedures is also adding impetus to the market.

Segment-

Passive Hemostats Segment to Hold Dominance Owing to Improved Patient Outcomes

Based on segmentation by product, the passive hemostats segment earned a 48.1% share in 2017 and gained dominance owing to various advantages offered by this segment. This includes minimal complications, improved patient outcomes, and cost-efficiency.

The rising prevalence of unwanted pregnancies is boosting the global contraceptive drugs market. In a report, titled “Contraceptive Drugs Market Size, Share and Global Trend By Product Type (Oral, Injectable, Patches), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Clinics, Online Channel, Public Channel & NGOs) and Geography Forecast till 2025” Fortune Business Insights identifies various factors enabling growth in the market.

According to the report, the global contraceptive drugs market is anticipated to rise at 5.8% CAGR and reach a value of US$ 20,200.5 Mn by 2025 from US$ 13,097.7 Mn in 2017. Remarkably improving access to contraceptive pills around the world is a key factor propelling growth in this market.

For more information in the analysis of this report, visit: https://www.fortunebusinessinsights.com/industry-reports/contraceptive-drugs-market-100063

Key Players Operating in The Contraceptive Drugs Market Include:

Key players are involved in mergers and acquisition to strengthen their market position. Owing to increasing competition frequent innovations are taking place in the market. Some of the companies operating the industry are:

• Bayer AG

• Pfizer Inc.
• Janssen Global Services, LLC
• Teva Pharmaceutical Industries Ltd.
• Merck & Co., Inc.
• Mylan N.V.
• Allergan Plc
• Agile Therapeutics
• Piramal Enterprises Ltd.

Request a Sample Copy of the Research Report: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/contraceptive-drugs-market-100063

Rising Abortion Rates to Create Demand for Contraceptive Drugs

Under the Affordable Care Act (ACA) in the U.S., oral contraceptive pills are given free of cost to women in the U.S. Such regulations favor the growth of the contraceptive drugs market. Increasing government initiatives to reduce infant mortality due to early pregnancies will increase the demand for oral contraceptives. Contraceptive drugs not only help to control unwanted pregnancies but also reduce the number of abortion and complications associated with the procedure worldwide. As per the World Health Organization, there is an estimated 40 to 50 million abortions every year, corresponding to an approximate of 125,000 abortions per day. To avoid unwanted and unplanned pregnancies, an increasing number of women are opting for contraceptive drugs. This will in turn augment growth in the global market.

Contrary to this, the market for contraceptive drugs may face challenges posed by religious, ethical, and social barriers especially in more conservative regions. Social taboos often discourage the use of contraceptive drugs among women, subsequently adversely impacting the overall market.

Government Initiatives to Promote Use of Contraceptive Medicines

Geographically, North America held dominance in the global contraceptive drugs market owing to the presence of leading players in the region. This, accompanied with easy availability of contraceptive drugs, has catapulted North America to the fore of the global market. However, Asia Pacific is most likely to emerge as the fastest growing region. This is owing to government initiatives adopted across emerging nations of this region. These initiatives are intended at promoting the use of contraceptive medicines as a convenient way of preventing unwanted pregnancy.

The increasing prevalence of psoriasis around the world is boosting the global psoriasis treatment market, says Fortune Business Insights in their recent report. The report is titled “Psoriasis Treatment Market: Global Market Analysis, Insights, and Forecasts, 2018 – 2025.” According to the report, the market will reach US$ 37,634.2 Mn by 2026 from US$ 18,378.0 Mn in 2018, exhibiting a CAGR of 8.2% between 2018 and 2026.

According to the report prepared by Fortune Business Insights, the TNF inhibitors segment emerged dominant among drug classes. In 2018, the TNF inhibitor segment held 46.3% share in the market. However, in the coming years, the market may witness higher demand for biosimilar version leading to the decline in the price of TNF inhibitors. This, accompanied by the increasing prescription volume for interleukin inhibitors segment may help the interleukin inhibitors to emerge as the dominant segment in the coming years.

 Please visit: https://www.fortunebusinessinsights.com/industry-reports/psoriasis-treatment-market-100600

Key Players Operating in The Psoriasis Treatment Market Include:

Key players are involved in mergers and acquisition to strengthen their market position. Owing to increasing competition frequent innovations are taking place in the market. Some of the companies operating the industry are:

• Merck & Co., Inc.,
• LEO Pharma A/S,
• Pfizer Inc.,
• Sun Pharmaceutical Industries Ltd,
• AbbVie Inc.,
• UCB S.A.,
• Amgen Inc.,
• Johnson & Johnson Services, Inc.,
• Eli Lilly and Company,

Request a Sample Copy of the Research Report: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/psoriasis-treatment-market-100600

An Overview of the Impact of COVID-19 on this Market:

The emergence of COVID-19 has brought the world to a standstill. We understand that this health crisis has brought an unprecedented impact on businesses across industries. However, this too shall pass. Rising support from governments and several companies can help in the fight against this highly contagious disease. There are some industries that are struggling and some are thriving. Overall, almost every sector is anticipated to be impacted by the pandemic.

Rising Prevalence of Plaque Psoriasis to Increase Demand for Treatment, Boosting Market

One of the major factor boosting the global psoriasis treatment market is the increasing prevalence of the disease itself. The World Health Organization states that the prevalence of psoriasis is estimated to vary between 0.09% to 11.0% across all nations. This ultimately means that psoriasis is a serious problem. Psoriasis can occur to anyone irrespective of age but is usually reported to occur to aged people between 50 to 70 years. The rising geriatric population and their vulnerability towards diseases such as psoriatic arthritis are factor propelling growth of the market. These, coupled with the rising prevalence of plaque psoriasis, are likely to create growth opportunities for the market in the forecast period.

The rising availability of biologic and biosimilar products is helping the market for psoriasis grow rapidly. Increase in prescription volume of the biologic products and favorable reimbursement policies by governments are also helping the market grow and continue doing so in the forecast duration as well.

Rising prevalence of chronic wounds and increasing availability of advanced wound dressings are propelling the growth of advanced wound dressings market says Fortune Business Insights in a published report titled “Advanced Wound Dressings Market Size, Share and Global Trend By Product Type (Alginate Dressings, Hydrogel Dressings, Film Dressings, Hydrocolloid Dressings, Antimicrobial Dressings, Foam Dressings), Indication (Diabetic Foot Ulcers, Pressure Ulcers, Surgical Wounds), End Users (Hospitals, Clinics, Home Care Settings) and Geography Forecast till 2025.”Global advanced wound dressings market to grow at significant a CAGR of 4.6% From 2018-2025, owing to the constant focus of key players on R&D to launch new products.

some of the key players in the global Advanced Wound Dressings Market:

• Derma Sciences Inc.
• Coloplast Corp
• ConvaTec Inc.
• Tissue Regenix
• Mölnlycke Health Care AB
• Smith & Nephew
• Organogenesis Inc.
• KCI Licensing, Inc

For more information in the analysis of this report, visit: https://www.fortunebusinessinsights.com/industry-reports/advanced-wound-dressings-market-100384

Intoduction of Alginate Dressing to Have Major Contribution in The Global Market

Chronic wounds are also treated by alginate dressing. It is primarily used due to its exponential benefits such as promoting tissue formation, higher efficiency in exudate management, improved healing of the wound. The demand for alginate dressing along with the rising cases of chronic wounds are contributing significantly to the growth of the global advanced wound dressing market. For Instance, in 2017, alginate segment was accounted for 11.8% share of the global advanced wound care market. Further the global wound care dressings market is segmented on the basis of indication into, pressure ulcers, diabetic foot ulcers surgical wounds, and others.

Asia-Pacific to Account for Highest Share in The Global Market

Asia Pacific region was valued at US$ 1,916.0 Mn in 2017 and is predicted to grow at a significantly high CAGR during the forecast period. According to a survey conducted by the United Nations, the Japanese have the highest life expectancy/life-span among all the countries in the world. Besides Japan other countries in Asia Pacific such as India and China also account for a significant share in the global market. The rising prevalence of chronic diseases directing towards longer hospital stays for patients is fostering the growth of the global advanced wound dressings market. Reduced mobility in the region along with rising incidences of chronic diseases are the factors attributing to pressure ulcers and hence enabling growth of the global advanced wound dressings market. Nevertheless, lack of reimbursement policies in Asia Pacific for advanced wound dressings is the factor hampering the growth for advanced wound dressings market.

Request a Sample Copy of the Global Advanced Wound Dressings Market Research Report: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/advanced-wound-dressings-market-100384

The global advanced wound dressings market key players are Derma Sciences Inc., Coloplast Corp, ConvaTec Inc., Tissue Regenix, Mölnlycke Health Care AB, Smith & Nephew, Organogenesis Inc., KCI Licensing, Inc, Other Prominent Players

Table of Content from advanced wound dressings market:

1. Introduction

1.1. Research Scope

1.2. Market Segmentation

1.3. Research Methodology

1.4. Definitions and Assumptions

2. Executive Summary
3. Market Dynamics

3.1. Market Drivers

3.2. Market Restraints

3.3. Market Opportunities

4. Key Insights

4.1. Prevalence of Key Indications, 2017 (Key Countries)

4.2. Economic cost Burden, Chronic Wounds (Key Countries)

4.3. Key Mergers & Acquisitions

The Hemostats Market in the Asia Pacific is expected to grow at a relatively higher CAGR. Baxter (the leading organization in the global market), plans to expand its operation in emerging nations such as India and China to enhance its accessibility. This is expected to propel the growth rate of the Asia Pacific Hemostats market. Meanwhile, the Europe market is likely to expand at a low CAGR due to the presence of a smaller patient pool compared to the Asia Pacific and North America.

Browse Complete Report Details@ https://www.fortunebusinessinsights.com/industry-reports/hemostatic-agents-market-100084

Some of the Main Key Players Covered in the Report

• Medtronic
• Ethicon LLC.
• Pfizer Inc.
• Biom’up
• Baxter International Inc.
• Stryker
• CryoLife Inc.
• Integra Life Sciences
• BD

Combination Hemostats to Dominate the Global Market

In terms of product type, the combination hemostats segment accounted for 14% of the global market in 2017. Combination hemostats are proven to be very effective and offer faster healing. Combination hemostats are capable of offering efficient hemostasis in shorter time owing to the rapid action of thrombin and gelatin. Rising adoption of combination hemostats is anticipated to drive the global Hemostats market during the forecast period 2018-2025.

The factors expected to drive the global Hemostats market are increasing the incidence of hemorrhage during surgery and a rising emphasis on blood management. Moreover, innovations in a surgical procedure such as robot-assisted surgery and rising geriatric population are anticipated to fuel the demand in global Hemostats market.

Request Sample PDF: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/hemostatic-agents-market-100084

Drivers & Restraints-

Rising Number of Sports Injuries to Augment Growth

The increasing number of accidental cases and the rise in the number of surgical procedures are the major factors promoting hemostat market growth. Additionally, the increasing emphasis on sports and physical activities and the rising number of sports injuries is also expected to aid in the expansion of the market. Besides this, the increasing prevalence of chronic diseases that requires surgical treatment procedures is also adding impetus to the market.

Regional Analysis-

North America to Dominate Market on Account of Presence of Increasing Number of Ambulatory Patients Opting Surgery

Geographically, North America earned a revenue of USD 1.17 billion in 2017 and emerged dominant, attributable to the rise in the number of surgeries and supported interventions for controlling blood loss during operations from the government. This, coupled with the high rate of hospital visits including both inpatient and ambulatory patients opting for therapeutic and invasive surgeries are likely to help this region continue dominating the market in the forthcoming years.

The rising prevalence of unwanted pregnancies is boosting the global contraceptive drugs market. In a report, titled “Contraceptive Drugs Market Size, Share and Global Trend By Product Type (Oral, Injectable, Patches), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Clinics, Online Channel, Public Channel & NGOs) and Geography Forecast till 2025” Fortune Business Insights identifies various factors enabling growth in the market.

For more information in the analysis of this report, visit: https://www.fortunebusinessinsights.com/industry-reports/contraceptive-drugs-market-100063

Leading Players operating in the Contraceptive Drugs Market are:

Key players are involved in mergers and acquisition to strengthen their market position. Owing to increasing competition frequent innovations are taking place in the market. Some of the companies operating the industry are:

• Bayer AG

• Pfizer Inc.
• Janssen Global Services, LLC
• Teva Pharmaceutical Industries Ltd.
• Merck & Co., Inc.
• Mylan N.V.
• Allergan Plc
• Agile Therapeutics
• Piramal Enterprises Ltd.

According to the report, the global contraceptive drugs market is anticipated to rise at 5.8% CAGR and reach a value of US$ 20,200.5 Mn by 2025 from US$ 13,097.7 Mn in 2017. Remarkably improving access to contraceptive pills around the world is a key factor propelling growth in this market.

Request a Sample Copy of the Research Report: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/contraceptive-drugs-market-100063

Rising Abortion Rates to Create Demand for Contraceptive Drugs

Under the Affordable Care Act (ACA) in the U.S., oral contraceptive pills are given free of cost to women in the U.S. Such regulations favor the growth of the contraceptive drugs market. Increasing government initiatives to reduce infant mortality due to early pregnancies will increase the demand for oral contraceptives. Contraceptive drugs not only help to control unwanted pregnancies but also reduce the number of abortion and complications associated with the procedure worldwide. As per the World Health Organization, there is an estimated 40 to 50 million abortions every year, corresponding to an approximate of 125,000 abortions per day. To avoid unwanted and unplanned pregnancies, an increasing number of women are opting for contraceptive drugs. This will in turn augment growth in the global market.

Contrary to this, the market for contraceptive drugs may face challenges posed by religious, ethical, and social barriers especially in more conservative regions. Social taboos often discourage the use of contraceptive drugs among women, subsequently adversely impacting the overall market.

Government Initiatives to Promote Use of Contraceptive Medicines

Geographically, North America held dominance in the global contraceptive drugs market owing to the presence of leading players in the region. This, accompanied with easy availability of contraceptive drugs, has catapulted North America to the fore of the global market. However, Asia Pacific is most likely to emerge as the fastest growing region.

The global wound care market size is projected to showcase significant progress and earn USD 24.55 billion by 2027. This is accountable to the increasing prevalence of chronic diseases such as diabetes, blood pressure, and the wounds that result from them, such as diabetic foot ulcers and pressure ulcers. Wound care is used for injuries that are unable to heal by themselves. If untreated, they may result in severe consequences, such as mobility issues, decreased elasticity of blood vessels, and others. A recent report by Fortune Business Insights offers an elaborative overview of the market. The report is titled, “Wound Care Market Size, Share & Covid-19 Impact Analysis, By Type (Advanced Wound Dressing, Traditional Wound Care Products, Negative Pressure Wound Therapy, Bioactives, and Others), By Application (Chronic Wounds, and Acute Wounds), By End User (Hospitals, Clinics, Homecare Settings, and Others), and Regional Forecast, 2020-2027.” According to this report, the market value stood at USD 15.68 billion in 2019 and is likely to exhibit a CAGR of 6.0% between 2020 to 2027.

Please visit: https://www.fortunebusinessinsights.com/wound-care-market-103268

As per a report by Fortune Business Insights™, some of the significant players in the market are as follows:

• Johnson & Johnson Services, Inc.
• Smith & Nephew
• Coloplast Corp
• Cardinal Health
• ConvaTec Inc.
• Medtronic
• 3M
• BSN Medical (Essity)
• PAUL HARTMANN AG
• Other players

Request a Sample Copy of the Research Report: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/wound-care-market-103268

Regional Analysis-

North America is Holding Dominance on Account of Well-established Healthcare Infrastructure

North America earned a revenue of USD 6.09 billion in 2019 and emerged dominant, followed by Europe. This is on account of the increasing prevalence of acute and chronic wounds. This coupled with the presence of well-established healthcare infrastructure and facilities, as well as favorable reimbursement policies by the governments of developed nations are likely to aid in the expansion of the regional market.

On the other side, the market in Asia Pacific is likely to exhibit rapid growth in the coming years on account of the increasing prevalence of acute and chronic diseases as a result of the rising patient population and improving healthcare and medical infrastructure.

 Segment:

Advanced Wound Dressing Segment to earn Largest Share Owing to Better Product Offering

Based on segmentation by type, the advanced wound dressing segment earned 42.6% wound care market share in 2019 and emerged dominant. This is owing to the presence of a diverse product portfolio.

Regional Analysis-

North America is Holding Dominance on Account of Well-established Healthcare Infrastructure

North America earned a revenue of USD 6.09 billion in 2019 and emerged dominant, followed by Europe. This is on account of the increasing prevalence of acute and chronic wounds. This coupled with the presence of well-established healthcare infrastructure and facilities, as well as favorable reimbursement policies by the governments of developed nations are likely to aid in the expansion of the regional market.

The global veterinary/animal vaccines market size is projected to hit USD 16.01 billion by the end of 2026 attributed to the increasing awareness about animal diseases and the increasing importance of animal health and welfare. Animals are exposed to various internal and external factors that act as disease-causing agents, thereby leading to communicable or fatal animal diseases. Therefor animal vaccination is a significant factor that allows humans and animals to share the same environment, especially for pet owners. As per a recent report by Fortune Business Insights titled, “Veterinary/Animal Vaccines Market Size, Share & Industry Analysis, By Product (Inactivated, Live Attenuated, Recombinant, Others), By Animal (Companion, Livestock), By Route of Administration (Oral, Parenteral, Others), By Distribution Channel (Veterinary Hospitals, Veterinary Clinics, Pharmacies & Drug Stores, Others) and Regional Forecast, 2019-2026,” the market value was USD 9.75 billion in 2018 and is expected to exhibit a CAGR of 6.4% between 2019 to 2026, set as the forecast duration.

 Please visit: 

https://www.fortunebusinessinsights.com/industry-reports/veterinary-animal-vaccines-market-101532

Fortune Business Insights™ lists out the names of market manufacturers. They are as follows:

• Ceva
• NEOGEN CORPORATION
• Boehringer Ingelheim International GmbH
• ImmuCell Corporation
• Eli Lilly and Company
• Merial
• Intervet Inc. (Merck Animal Health)
• Biovac
• Virbac
• Zoetis
• Other players

Request a Sample Copy of the Research Report: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/veterinary-animal-vaccines-market-101532

Objectives of the Report include:

• Comprehensive analysis of the market and its growth trajectories
• Table of segmentation in details with the list of the key segment and its forecasted figure
• Notable industry developments of the market and other insights
• List of players and their key strategies to generate the highest revenue and emerge dominant

Drivers & Restraints-

Rise in Number of Zootonic Diseases Worldwide to Propel Demand

The increasing number of farm animals and pet owners worldwide and the importance given to the health and well-being of their pets are major factors boosting the veterinary vaccines market growth. Additionally, the increasing number of animal cultivation practices for benefits such as milk, meat, eggs, wool, and others is also adding impetus to the market. Besides this, the rise in the number of zoonotic diseases and the increasing number of veterinary health care centers is expected to aid in the expansion of the market in the coming years.

On the negative side, the adverse effects of vaccines on some animals such as fever, uveitis, anorexia, and high toxicity may pose a major hindrance to the market in the future. Nevertheless, awareness programs organized by various governments, and improving healthcare infrastructure for animal welfare is likely to create lucrative growth opportunities for the market in the coming years.

Competitive Landscape-

Players Focusing on Developing Vaccines for Better Revenue Generation

The veterinary vaccines market manufacturers are engaging in the launch of vaccines for various animal diseases and are investing massively on the same. Besides this, they are engaging in collaboration and joint ventures to gain more revenue in the competition.

According to a report published by Fortune Business Insights, titled, “Autism Spectrum Disorder Therapeutics Market: Global Market Analysis, Insights and Forecast, 2018-2026,” the global market is likely to reach US$ 4,612.1 Mn by 2026 owing to the rising incidence of autism spectrum disorder worldwide. The report provides valuable insights into the global market trends and factors that are directly affecting the growth of the market. As per the report, the global autism spectrum disorder therapeutics market was worth US$ 3,293.0 Mn in 2018. Considering the increasing awareness programs regarding this particular disorder and less availability of treatment options, the global market is expected to rise at a moderate CAGR of 4.3% during the forecast period (2019-2026).

The report further states that the number of children diagnosed with autism is increasing day by day across the globe. This, combined with favorable reimbursement scenario, will increase the demand for applied behavioral analysis therapies. Such therapies aid in improving learning and physical disabilities in autistic children. Furthermore, FDA approvals of numerous medicines that are used to manage autism spectrum disorder are expected to propel the global autism spectrum disorder therapeutics market during the forecast period.

For more information in the analysis of this report, visit: https://www.fortunebusinessinsights.com/industry-reports/autism-spectrum-disorder-therapeutics-market-101207

Key Players Operating in The Autism Spectrum Disorder Therapeutics Market Include:

Key players are involved in mergers and acquisition to strengthen their market position. Owing to increasing competition frequent innovations are taking place in the market. Some of the companies operating the industry are:

• Applied Behavior Consultants,
• Allergan,
• Pfizer Inc.,
• Q BioMed Inc,
• Fusion Autism Center,
• AstraZeneca,
• Hopebridge, LLC.,
• Johnson & Johnson Services, Inc.,
• Behavior Innovations,
• Eli Lilly and Company,
• Otsuka Holdings Co. Ltd.,
• other prominent market players.

Autistic Disorder Segment to Witness Growth Owing to the Rising Prevalence of the Disease

The global autism spectrum disorder therapeutics market is grouped into drug therapy and communication and behavioral therapy in terms of treatment type. Amongst these, the communication and behavioral therapy segment was in the leading position in the global market. Fortune Business Insights predicts that it will retain its position throughout the forecast period. In terms of type, the autism spectrum disorder therapeutics market is classified into Asperger syndrome, autistic disorder, pervasive development disorder, and others. Out of these, the autistic disorder segment procured the highest autism spectrum disorder therapeutics market share in the year 2018. It is anticipated to witness significant growth in the coming years. This growth is attributed to the increasing prevalence of this disorder.

Request a Sample Copy of the Research Report: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/autism-spectrum-disorder-therapeutics-market-101207

Detailed Table of Content:

1. Introduction
   • Research Scope
   • Market Segmentation
   • Research Methodology
   • Definitions and Assumptions
2. Executive Summary
3. Market Dynamics
   • Market Drivers
   • Market Restraints
   • Market Opportunities
4. Key Insights
   • Prevalence of Autism Spectrum Disorder for Key Countries/Region
   • Recent Industry Developments Such As Partnerships, Mergers, & Acquisitions
   • Regulatory Framework by Key Countries
   • Global Reimbursement Scenario and Economic Cost Burden for the Treatment of Autism Spectrum Disorder by Key Countries/Region

The global microfluidic devices market is expected to gain impetus from increasing technological advancements in the biotechnology domain. According to a report by Fortune Business Insights, titled, “Microfluidic Devices Market Size, Share & Industry Analysis, By Device Type (Chips, Sensors, and Others), By Material (Glass, Silicon, PDMS and Others), By Applications (Pharmaceutical & Life Science Research, Diagnosis & Treatment, and Others), By End-user (Diagnostic Centers, Research Institutes, Pharmaceutical and Biotechnology Companies, Healthcare Facilities and Others) and Regional Forecast, 2019-2026,” the market is projected to reach USD 22.65 Billion by 2026, thereby exhibiting a CAGR of 20.5% during the forecast period. However, the global microfluidic devices market size was valued at USD 5.14 Billion in 2018. The report further states that renowned market players are focusing on low-cost materials for manufacturing microfluidic sensors and chips. It would contribute to the market growth in the forthcoming years.

For more information in the analysis of this report, visit: https://www.fortunebusinessinsights.com/industry-reports/microfluidic-devices-market-101098

Fortune Business Insights profiles some of the renowned companies operating in the global microfluidic devices market. They are as follows:

• uFluidix
• Perkin Elmer
• Fluidigm
• Blacktrace Holdings Ltd. (Dolomite Microfluidic)
• Micronit
• BioFluidix GmbH‎
• Fluigent
• ALine, Inc.
• Philips
• Other prominent players

Rising Usage of Microfluidic Devices to Boost Growth of Pharmaceutical and Biotechnology Companies Segment

In terms of end-user, the global microfluidic devices market is grouped into pharmaceutical and biotechnology companies, research institutes, diagnostic centers, and healthcare facilities and others. Out of these, the pharmaceutical and biotechnology companies segment is projected to lead the global market by acquiring the highest revenue in terms of share. It would occur due to the increasing manufacturing and usage of sensors, chips, and other microfluidic devices to offer novel and robust devices to the consumers. However, diagnostic centers and research institutes will also grow rapidly during the forecast period by utilizing microfluidic devices for various applications.

Request a Sample Copy of the Global Microfluidic Devices Market Research Report: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/microfluidic-devices-market-101098

Highlights of the Report

• In-depth analysis of various insights, namely, Microfluidic Devices Market trends, growth drivers, opportunities, and other related challenges.
• Comprehensive details of key market players, their core competencies, and market shares.
• The potency of suppliers and buyers to make better business decisions.
• Lists out the market size in terms of volume.

Schott AG Acquires MINIFAB to Develop Top-quality Polymer and Glass Solutions

Schott AG, a company specializing in the production of glass and glass-ceramics, based in Germany, declared that it has completed its acquisition of MINIFAB PTY Ltd., a provider of custom-designed and manufactured microfluidic and medical devices, based in Australia in June 2019. This strategic collaboration will enable both companies to upgrade their portfolios in the diagnostics market. They will be able to provide the products to their existing consumers as well as serve new consumers effectively in the upcoming years by developing centers of excellence for glass in Germany and polymer in Australia. MINIFAB is an expert in business development.